222 related articles for article (PubMed ID: 20857093)
1. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
Kummer O; Hammann F; Moser C; Schaller O; Drewe J; Krähenbühl S
Eur J Clin Pharmacol; 2011 Jan; 67(1):63-71. PubMed ID: 20857093
[TBL] [Abstract][Full Text] [Related]
2. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):919-30. PubMed ID: 20590588
[TBL] [Abstract][Full Text] [Related]
4. Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study.
Grönlund J; Saari TI; Hagelberg NM; Neuvonen PJ; Laine K; Olkkola KT
Clin Drug Investig; 2011; 31(3):143-53. PubMed ID: 21142269
[TBL] [Abstract][Full Text] [Related]
5. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.
Grönlund J; Saari TI; Hagelberg NM; Neuvonen PJ; Olkkola KT; Laine K
Br J Clin Pharmacol; 2010 Jul; 70(1):78-87. PubMed ID: 20642550
[TBL] [Abstract][Full Text] [Related]
6. Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients.
Lemberg KK; Heiskanen TE; Neuvonen M; Kontinen VK; Neuvonen PJ; Dahl ML; Kalso EA
Scand J Pain; 2010 Jan; 1(1):24-33. PubMed ID: 29913934
[TBL] [Abstract][Full Text] [Related]
7. Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone.
Grönlund J; Saari T; Hagelberg N; Martikainen IK; Neuvonen PJ; Olkkola KT; Laine K
J Clin Pharmacol; 2010 Jan; 50(1):101-8. PubMed ID: 19755414
[TBL] [Abstract][Full Text] [Related]
8. Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation.
Klose M; Cristofoletti R; Silva CM; Mangal N; Turgeon J; Michaud V; Lesko LJ; Schmidt S
Eur J Pharm Sci; 2024 Mar; 194():106689. PubMed ID: 38171419
[TBL] [Abstract][Full Text] [Related]
9. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.
Troost J; Tatami S; Tsuda Y; Mattheus M; Mehlburger L; Wein M; Michel MC
Br J Clin Pharmacol; 2011 Aug; 72(2):247-56. PubMed ID: 21496064
[TBL] [Abstract][Full Text] [Related]
10. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone.
Saari TI; Grönlund J; Hagelberg NM; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
Eur J Clin Pharmacol; 2010 Apr; 66(4):387-97. PubMed ID: 20076952
[TBL] [Abstract][Full Text] [Related]
11. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.
Lalovic B; Phillips B; Risler LL; Howald W; Shen DD
Drug Metab Dispos; 2004 Apr; 32(4):447-54. PubMed ID: 15039299
[TBL] [Abstract][Full Text] [Related]
12. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
Heiskanen T; Olkkola KT; Kalso E
Clin Pharmacol Ther; 1998 Dec; 64(6):603-11. PubMed ID: 9871425
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone.
Kaiko RF; Benziger DP; Fitzmartin RD; Burke BE; Reder RF; Goldenheim PD
Clin Pharmacol Ther; 1996 Jan; 59(1):52-61. PubMed ID: 8549034
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole drastically increases exposure to oral oxycodone.
Hagelberg NM; Nieminen TH; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
Eur J Clin Pharmacol; 2009 Mar; 65(3):263-71. PubMed ID: 18836708
[TBL] [Abstract][Full Text] [Related]
15. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study.
Andreassen TN; Eftedal I; Klepstad P; Davies A; Bjordal K; Lundström S; Kaasa S; Dale O
Eur J Clin Pharmacol; 2012 Jan; 68(1):55-64. PubMed ID: 21735164
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
Lalovic B; Kharasch E; Hoffer C; Risler L; Liu-Chen LY; Shen DD
Clin Pharmacol Ther; 2006 May; 79(5):461-79. PubMed ID: 16678548
[TBL] [Abstract][Full Text] [Related]
17. Observations of urinary oxycodone and metabolite distributions in pain patients.
Elder NM; Atayee RS; Best BM; Ma JD
J Anal Toxicol; 2014 Apr; 38(3):129-34. PubMed ID: 24523296
[TBL] [Abstract][Full Text] [Related]
18. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism.
Zwisler ST; Enggaard TP; Noehr-Jensen L; Pedersen RS; Mikkelsen S; Nielsen F; Brosen K; Sindrup SH
Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):335-44. PubMed ID: 19281600
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers.
Liukas A; Hagelberg NM; Kuusniemi K; Neuvonen PJ; Olkkola KT
J Clin Psychopharmacol; 2011 Jun; 31(3):302-8. PubMed ID: 21508859
[TBL] [Abstract][Full Text] [Related]
20. Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients.
Naito T; Tashiro M; Ishida T; Ohnishi K; Kawakami J
J Clin Pharmacol; 2013 Aug; 53(8):812-8. PubMed ID: 23733622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
